Minming Li
Peking Union Medical College
9 Papers
7 Citations
Minming Li is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: T cell & Leukemia. The author has an hindex of 2, co-authored 9 publications.
Chat about Author
Papers
•Journal Article
Co-occurrence of RUNX1 and ASXL1 mutations underlie poor response and outcome for MDS patients treated with HMAs
Ping Wu,Jianyu Weng,Minming Li,Zesheng Lu,Chengxin Deng,Qihui Sun,Ruohao Xu,Suxia Geng,Xin Du +8 more
TL;DR: RUNX1 mutations are frequently found in MDS patients with ASXL1-mutations, and Co-occurrence of RUNX1 and ASXL 1 mutations are associated with poor response to HMAs and inferior survival.
18
•Journal Article
Concurrence of Myelodysplastic syndromes and large granular lymphocyte leukemia: clinicopathological features, mutational profile and gene ontology analysis in a single center.
Kexin Ai,Minming Li,Ping Wu,Chengxin Deng,Xin Huang,Wei Ling,Ruohao Xu,Suxia Geng,Qihui Sun,Jianyu Weng,Xin Du,Xin Du +11 more
TL;DR: The concurrence of myelodysplastic syndromes (MDS) and large granular lymphocyte leukemia (LGLL) has been reported in a small group of patients and might suggest an etiologic relationship rather than a simple coincidence as mentioned in this paper.
6
The efficacy and safety of CAR-T cell therapy in patients with refractory ALL and concomitant HBV infection.
Peilong Lai,Peilong Lai,Xiaomei Chen,Le Qin,Zhiwu Jiang,Chenwei Luo,Xin Huang,Sujing Wu,Wei Ling,Yulian Wang,Jinghua Wang,Chenxin Deng,Lisi Huang,Lingji Zeng,Zesheng Lu,Li-Ye Zhong,Pengjun Liao,Minming Li,Dongmei Chen,Suxia Geng,Ping Wu,Zhaoyang Tang,Duanqing Pei,Xin Du,Peng Li,Jianyu Weng +25 more
TL;DR: To evaluate the impact of HBV infection on CAR-T cell therapy and the risk of fulminant hepatitis, the situations of three relapsed/refractory B-ALL patients with concomitantHBV infection from the clinical trial are retrospectively reviewed.
6
•Journal Article
A retrospective study comparing azacitidine with decitabine in Chinese patients with refractory anemia with excess blast based on two clinical trials in a single center
Ruohao Xu,Ruohao Xu,Xiaomei Chen,Chengxin Deng,Ping Wu,Minming Li,Suxia Geng,Peilong Lai,Zesheng Lu,Jianyu Weng,Jianyu Weng,Xin Du,Xin Du +12 more
TL;DR: A trend of higher percentage of neutropenia, leukopenia and anemia as well as treatment delays were seen during the first 6 cycles in the DAC group, and patients treated with DAC showed slightly higher incidence of severe hematological adverse events during the whole treatment.
4
Decitabine With or Without Micro-Transplantation for the Treatment of Intermediate or High-Risk Myelodysplastic Syndrome: A Chinese Single-Center Retrospective Study of 22 Patients.
Minming Li,Chao Li,Chao Li,Suxia Geng,Xiaomei Chen,Ping Wu,Chengxin Deng,Xiaofang Chen,Zesheng Lu,Jianyu Weng,Jianyu Weng,Xin Du,Xin Du +12 more
TL;DR: In this paper, the authors evaluated the safety and efficacy of human leukocyte antigen mismatched hematopoietic stem cell micro-transplantation (MST) in patients with MDS.